Adipogenix Appoints Nils Bergenhem, Ph.D. as Chief Scientific Officer
BOSTON, June 17, 2005 – AdipoGenix Inc., a biopharmaceutical company developing small molecule therapies for obesity, type 2 diabetes and associated co-morbidities, today announced the appointment of Nils Bergenhem, Ph.D. as Chief Scientific Officer. Dr. Bergenhem will oversee internal drug discovery and development programs, including advancement of the Company’s proprietary lead compounds AGX-0104 and AGX-0119 toward IND filings, and the discovery and development activities of AdipoGenix’ alliance with Johnson & Johnson Pharmaceuticals.
“Nils has over 16 years of experience in the metabolic disease arena, which includes managing drug discovery and development, and we are very fortunate to have an individual with his experience and accomplishments to lead our science as we transition AdipoGenix to a clinical stage company,” said Ed Cannon, Ph.D., CEO of AdipoGenix. “Dr. Bergenhem has also managed or co-managed several international collaborative programs, including the Novo Nordisk - Boehringer Ingelheim collaboration, and the OSI - Tanabe Seiyaku CO., Ltd. programs. I look forward to working closely with Nils as we advance development of our proprietary product candidates and form additional partnerships that leverage our novel human fat-based discovery technology.”
Before joining AdipoGenix, Dr. Bergenhem was Vice President of Research at the Institute for Diabetes Discovery (IDD), where he managed the development of small molecule drugs for the treatment of diabetes, diabetic complications, and obesity. Before joining IDD, Dr. Bergenhem held the position as Director for Diabetes Research at OSI Pharmaceuticals Inc. and was responsible for building OSI’s diabetes program in New York and spinning out the diabetes program to OSI’s subsidiary, Prosidion Ltd. of Oxford, England. Prior to OSI, Dr. Bergenhem was employed by Novo Nordisk in Copenhagen, heading up a department focused on addressing dyslipideamia in type 2 diabetics. Dr. Bergenhem earned a Ph.D. in Biochemistry from Umeaa University, Sweden. He completed postdoctoral training at University of Michigan in Molecular Biology and Human Genetics, where he was also a Research Investigator at the Institute of Gerontology and at the Department of Biological Chemistry in the School of Medicine.
“AdipoGenix’ human fat cell-based discovery technology is unique and avoids the shortcomings of target-based drug discovery and reliance on poorly predictive animal models,” said Nils Bergenhem. “Targeting fat should avoid the safety and side-effect issues encountered with other approaches for treating obesity and metabolic diseases. Furthermore, we believe drugs that target fat are likely to have a significantly greater effect on body weight and fat content. I am quite excited to be a part of this distinctive approach.”
About AdipoGenix Inc.
AdipoGenix is a Boston-based biopharmaceutical company developing pharmaceuticals that target human fat tissue to treat obesity and its co-morbidities, including diabetes and cardiovascular disease. Through its proprietary human fat cell-based technology, AdipoGenix identifies nontoxic, small molecule compounds that reduce the fat content in human fat tissue, which is expected to provide therapeutic benefit for these important diseases.
President and CEO
MacDougall BioCommunications, Inc.